Cannabidiol on the Path from the Lab to the Cancer Patient: Opportunities and Challenges

Miguel Olivas-Aguirre, Liliana Torres-López, Kathya Villatoro-Gómez, Sonia Mayra Perez-Tapia, Igor Pottosin, Oxana Dobrovinskaya

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Cannabidiol (CBD), a major non-psychotropic component of cannabis, is receiving grow-ing attention as a potential anticancer agent. CBD suppresses the development of cancer in both in vitro (cancer cell culture) and in vivo (xenografts in immunodeficient mice) models. For critical evaluation of the advances of CBD on its path from laboratory research to practical application, in this review, we wish to call the attention of scientists and clinicians to the following issues: (a) the biological effects of CBD in cancer and healthy cells; (b) the anticancer effects of CBD in animal models and clinical case reports; (c) CBD’s interaction with conventional anticancer drugs; (d) CBD’s potential in palliative care for cancer patients; (e) CBD’s tolerability and reported side effects; (f) CBD delivery for anticancer treatment.

Original languageEnglish
Article number366
JournalPharmaceuticals
Volume15
Issue number3
DOIs
StatePublished - Mar 2022

Keywords

  • adverse effects
  • anticancer activity
  • anticancer treatment
  • cannabidiol
  • clinical trials
  • drug delivery
  • palliative care
  • pre-clinical studies
  • synergism

Fingerprint

Dive into the research topics of 'Cannabidiol on the Path from the Lab to the Cancer Patient: Opportunities and Challenges'. Together they form a unique fingerprint.

Cite this